Bottom line
CRVXX vs MRSAX: the short answer
CRVXX (MFS U.S. Government Cash Reserve Fund) and MRSAX (MFS Research International Fund) are both money market funds.
CRVXX is cheaper at 0.45% vs 0.99% — a difference of $54 a year per $10,000 invested.
Over five years, MRSAX returned +2.6% a year vs +2.1% for CRVXX.
MRSAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
CRVXX vs MRSAX side by side
| CRVXX | MRSAX | |
|---|---|---|
| Type | Money market fund | Mutual fund |
| Fund family | MFS | MFS |
| Category | Money Market | International Stock |
| Expense ratio | 0.45% | 0.99% |
| Annual cost per $10k | $45 | $99 |
| 10-yr cost on $10k (prospectus) | $1,782 | $1,728 |
| Max front load | 0% | 5.75% |
| 12b-1 fee | 1% | 0.25% |
| 1-yr return | +4.9% | −3.1% |
| 5-yr return (annualized) | +2.1% | +2.6% |
| 10-yr return (annualized) | +1.4% | +4.5% |
| Best quarter | — | +16.5% |
| Worst quarter | — | −19.7% |
| Net assets (fund) | — | $17.8B |
| Number of holdings | — | 121 |
| Portfolio turnover | — | 27% |
| Returns as of | Dec 31, 2024 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
CRVXX and MRSAX share none of their top holdings.
CRVXX top 10
MRSAX top 10
- Mizuho Financial Group Inc — 2.90%
- Schneider Electric SE — 2.82%
- Hitachi Ltd — 2.45%
- ASML Holding NV — 2.21%
- Taiwan Semiconductor Manufacturing Co Ltd — 2.21%
- Novartis AG — 2.12%
- TotalEnergies SE — 2.10%
- Tokyo Electron Ltd — 1.90%
- AstraZeneca PLC — 1.78%
- Linde PLC — 1.76%
FAQ
What is the difference between CRVXX and MRSAX?
CRVXX (MFS U.S. Government Cash Reserve Fund) and MRSAX (MFS Research International Fund) are both money market funds. CRVXX is cheaper at 0.45% vs 0.99% — a difference of $54 a year per $10,000 invested.
Which is cheaper, CRVXX or MRSAX?
CRVXX has the lower expense ratio (0.45%).
Should I own both CRVXX and MRSAX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.